Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Danofloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG known ✓ | P48736 | 5/20 | 0.47 |
| ▸ | PIK3CD known ✓ | O00329 | 3/20 | 0.47 |
| ▸ | PIK3R1 known ✓ | P27986 | 3/20 | 0.47 |
| ▸ | PIK3CA known ✓ | P42336 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | TOP2A | P11388 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Danofloxacin SCHEMBL30014294 | 1.00 | KDM4E (0.57) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Danofloxacin SCHEMBL149627 | 0.95 | KDM4E (0.62) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Danofloxacin SCHEMBL9669908 | 0.95 | KDM4E (0.62) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Danofloxacin SCHEMBL10073753 | 0.95 | KDM4E (0.62) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Danofloxacin SCHEMBL29658817 | 0.95 | KDM4E (0.62) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Danofloxacin SCHEMBL16518619 | 0.95 | KDM4E (0.62) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Danofloxacin SCHEMBL28372629 | 0.94 | KDM4E (0.61) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Danofloxacin SCHEMBL31592056 | 0.94 | KDM4E (0.54) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL9670553 | 0.90 | KDM4E (0.63) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Danofloxacin SCHEMBL31592064 | 0.89 | KDM4E (0.59) | KDM4EALDH1A1LMNAHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 346 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118191116-A | Method for detecting illegally added medicines in eucommia ulmoides leaf extract | 山东省饲料兽药质量检验中心 | 2024-06-14 | — | — | CN | claimed |
| CN-114191566-B | Method for preparing ZIF-8 composite nano material with magnetic targeting, antibacterial and developing functions | 上海交通大学 | 2023-09-29 | — | — | CN | claimed |
| CN-115368369-A | Synthesis method of demethylation impurity of danofloxacin mesylate | 浙江国邦药业有限公司 | 2022-11-22 | — | — | CN | claimed |
| CN-110060784-B | Drug resistance judgment standard test method for mycoplasma gallisepticum to danofloxacin | 华中农业大学 | 2022-11-08 | — | — | CN | claimed |
| US-20220249473-A1 | A NOVEL THERAPY FOR ERYTHROPOIETIC PROTOPORPHYRIA (EPP) AND X-LINKED PROTOPORPHYRIA (XLP) | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2022-08-11 | — | — | US | claimed |
| EP-3972605-A1 | A NOVEL THERAPY FOR ERYTHROPOIETIC PROTOPORPHYRIA (EPP) AND X-LINKED PROTOPORPHYRIA (XLP) | University of Pittsburgh - of the Commonwealth System of Higher Education (US) | 2022-03-30 | — | — | EP | claimed |
| CN-114191566-A | Method for preparing ZIF-8 composite nano material with magnetic targeting, antibacterial and developing functions | 上海交通大学 | 2022-03-18 | — | — | CN | claimed |
| CN-114105999-A | Synthesis method of danofloxacin mesylate | 浙江国邦药业有限公司 | 2022-03-01 | — | — | CN | claimed |
| CN-114096250-A | Novel therapy for erythropoietic protoporphyrinopathy (EPP) and X-linked protoporphyrinopathy (XLP) | 匹兹堡大学联邦高等教育系统 | 2022-02-25 | — | — | CN | claimed |
| CN-114010797-A | Bacteria-targeted nano antibacterial agent and preparation method thereof | 上海交通大学 | 2022-02-08 | — | — | CN | claimed |
| CN-101703469-A | Preparation method and products of danofloxacin mesylate liposome | UNIV NORTHEAST AGRICULTURAL | 2010-05-12 | — | — | CN | claimed |
| WO-2009088831-A2 | METHOD OF INHIBITING ABCG2 AND OTHER TREATMENT METHODS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-07-16 | — | — | WO | claimed |
| WO-2009061770-A2 | METHOD OF INHIBITING ABCG2 AND RELATED TREATMENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-05-14 | — | — | WO | claimed |
| CN-101411689-A | Danofloxacin mesylate microsphere formulation for livestock and poultry and preparation method thereof | HUBEI PIG VETERINARY MEDICINE (CN) | 2009-04-22 | — | — | CN | claimed |
| EP-1656018-A4 | EDIBLE FILMS FOR ADMINISTRATION OF MEDICAMENTS TO ANIMALS | INNOZEN INC (US) | 2008-07-23 | — | — | EP | claimed |
| CN-1965828-A | Dafloxacin mesylate solution containing hexacyclic ring water for animals | TIANJIN RINGTOP BIOTECHNOLOGY (CN) | 2007-05-23 | — | — | CN | claimed |
| EP-1656018-A1 | EDIBLE FILMS FOR ADMINISTRATION OF MEDICAMENTS TO ANIMALS | Innozen, Inc. (US) | 2006-05-17 | — | — | EP | claimed |
| US-20050136096-A1 | Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals | CUREX PHARMACEUTICAL MEXICO S.A.P.I. DE C.V. (MX) | 2005-06-23 | — | — | US | claimed |
| WO-2005018323-A1 | EDIBLE FILMS FOR ADMINISTRATION OF MEDICAMENTS TO ANIMALS | INNOZEN, INC. (US) | 2005-03-03 | — | — | WO | claimed |
| US-4861779-A | Anti-bacterial substituted bridged-diazabicycloalkyl quinolone carboxylic acids | PFIZER INC. (US) | 1989-08-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220249473-A1 | A NOVEL THERAPY FOR ERYTHROPOIETIC PROTOPORPHYRIA (EPP) AND X-LINKED PROTOPORPHYRIA (XLP) | XPA, TPX2, XPOT | PIK3CG 3451/4885PIK3CD 3690/4885PIK3R1 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.